HOB Biotech Group Corp Ltd

HOB Biotech released its 2026 interim report, with net profit attributable to the parent company of 16.6776 million yuan, up 37.05% from the same period last year. Total operating revenue was 196 million yuan, up 3.22% year-on-year; net cash inflow from operating activities was 37.2862 million yuan, up 60.20% year-on-year. The company's latest asset-liability ratio was 9.29%, down 7.55 percentage points from the same period last year; gross margin was 60.34%, up 1.16 percentage points year-on-year; diluted earnings per share was 0.27 yuan, up 42.11% year-on-year.

HOB Biotech's wholly-owned subsidiary, Hunan HOB Biotech Pharmaceutical Co., Ltd., has recently obtained seven medical device registration certificates approved by the Hunan Medical Products Administration. The products include allergen-specific IgE antibody detection kits for nut mix FX28, mold mix MX14, tree mix TX1, seafood mix FX3, fruit mix FX30, and grass mix WX1, as well as a Blomia tropicalis allergen-specific IgE antibody assay kit. All use magnetic particle chemiluminescence and are intended for auxiliary diagnosis of allergies. These new certificates enrich the company's chemiluminescence platform testing menu and help enhance market competitiveness, though actual sales will depend on future market expansion efforts.